We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00257556
First Posted: November 23, 2005
Last Update Posted: February 26, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ferring Pharmaceuticals
  Purpose
Prospective open label, randomised, parallel group, comparative pilot.

Condition Intervention Phase
Infertility Drug: Menotrophin Drug: Follitropin alfa Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open Label, Randomised, Parallel Group, Comparative Pilot Study to Study the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant FSH (Follitropin Alfa) Administered Subcutaneously to Subfertile Female Patients Undergoing IVF Using Antagonist Downregulation

Resource links provided by NLM:


Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Number of Participants With an Ongoing Pregnancy [ Time Frame: Approx week 13; 9 weeks or more after the 1st positive pregnancy test ]
  • Percentage of Participants With an Ongoing Pregnancy [ Time Frame: Approx week 13; 9 weeks or more after the first positive pregnancy test ]

Secondary Outcome Measures:
  • Participants With Varying Numbers of Follicles That Were Greater Than or Equal to 17 Millimeters [ Time Frame: Day 7 and, if appropriate, every 2 days thereafter (Days 9/11/13) ]
  • Participants With Varying Numbers of Oocytes Retrieved [ Time Frame: Approximately study day 15 ]
  • Participants With Varying Numbers of Pronuclear Stage Oocytes [ Time Frame: Approximately study day 15 ]
  • Participants With Varying Numbers of Embryos Transferred [ Time Frame: Approximately study day 17 ]
  • Participants With Varying Numbers of Embryos Frozen [ Time Frame: Approximately study day 17 ]
  • Mean Number of Days Stimulated With Gonadotrophins [ Time Frame: study days 1 - 13 ]
  • Pregnancy Outcomes [ Time Frame: Approximately 10 months ]
  • Mean Endometrial Thickness [ Time Frame: Day 7 or 9 or 11 or 13 ]
  • Mean Estradiol Level [ Time Frame: Day 7 or 9 or 11 or 13 ]

Enrollment: 80
Study Start Date: October 2005
Study Completion Date: April 2009
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Menotrophin Drug: Menotrophin
150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
Other Names:
  • Menopur
  • hMG
  • highly purified menotrophin
Active Comparator: Follitropin alfa Drug: Follitropin alfa
150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
Other Names:
  • rFSH
  • recombinant FSH

Detailed Description:
Ongoing pregnancy rate, defined as positive fetal heart action 9 weeks after the first positive pregnancy test. Number/diameter of follicles, number of oocytes retrieved, number of pronuclear oocytes (referred to as zygotes or pre-embryos in the UK), quality of pronuclear stage oocytes, number of embryos transferred, quality of embryos, number of frozen embryos, endometrial thickness and morphology on day of HCG administration, estradiol levels at day of HCG administration, implantation rate, number of days stimulated with gonadotrophins and number of ampoules used, clinical pregnancy rate at 6 weeks after the first positive pregnancy test, pregnancy outcome.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Female patients aged > or = 20 and < or = 35 years with a BMI of >18 and <32 kg/m2 who have received no more than two previous cycles of in vitro fertilisation (IVF) or other assisted reproductive technique (ART) and whose partners have normal sperm (according to WHO 1999 criteria).

Inclusion criteria:

  • Signed informed consent;
  • Subfertile premenopausal female patients eligible for IVF treatment;
  • Aged >=20 and <=35 years;
  • Body mass index of >18 and <32 kg/m2
  • Normal endocrine assessment within the last 6 months;
  • Normal pelvic ultrasound (showing two ovaries, no ovarian abnormalities and normal uterus) within the last 6 months;
  • Receipt of no more than two previous cycles of IVF (or other ART);
  • At least 3 consecutive ovulatory menstrual cycles of 24-35 days, and documented evidence of ovulatory cycles within the previous 12 months;
  • No fertility-modifying treatment within the 3 months prior to this treatment cycle;
  • Infertility attributable to or in association with either tubal factor, or unexplained causes;
  • Sperm of partner classed as normal according to WHO 1999 criteria within the year prior to beginning therapy;
  • Negative serum beta-HCG pregnancy test prior to beginning therapy;
  • Clinically normal baseline haematology, clinical chemistry, and urinalysis parameter values, negative serum HBsAg and HIV antibody tests;
  • Screening endocrine test results (estradiol, LH, FSH, progesterone, prolactin, TSH) in early follicular phase within the normal limits for the clinical laboratory.

Exclusion criteria

  • Presence of any clinically relevant systemic disease(e.g. insulin- dependent diabetes mellitus);
  • A history of or current endocrine disease, including polycystic ovary- like syndrome and hyperprolactinaemia;
  • A history of coagulation disorders;
  • Persistent ovarian cysts;
  • Contraindications for the use of gonadotrophins or GnRH antagonists;
  • A history of hypersensitivity to any of the constituents of the study medication or related compounds;
  • Three or more previous cycles of IVF (or other ART);
  • A history of alcohol abuse (more than 30 units per week on a regular basis);
  • History of chemo- or radiotherapy;
  • Currently breast-feeding, pregnant or with a contraindication to pregnancy;
  • Diagnosed poor responders in prior IVF treatment;
  • History of severe ovarian hyperstimulation syndrome (OHSS) (4 or 5) in former IVF treatment;
  • Investigational drug within the 30 days prior to treatment;
  • Any other condition or history that the investigator considers might increase the risk to the individual.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00257556


Locations
Germany
Gemeinschaftspraxis und Tagesklinik, Olpe 19
Dortmund, Germany, 44135
Universitats-Frauenklinik Heidelberg Abt. Gynakologische Endokrinologie und Fertilitatsstorungen, Voßstr. 9
Heidelberg, Germany, 69115
Gemeinschaftspraxis und Tagesklinik, Zingel 29
Hildesheim, Germany, 1134
United Kingdom
Royal Infirmary of Edinburgh, 51 Little France
Edinburgh, United Kingdom, EH16 4SA
Leeds General Infirmary, Great George Street
Leeds, United Kingdom, LS1 3EX
The Royal Hallamshire Hospital, University of Sheffield, Jessop Wing, Tree Root Walk
Sheffield, United Kingdom, S10 2SF
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Clinical Development Support, Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00257556     History of Changes
Other Study ID Numbers: FE999906 CS004 (PROSPECT)
2004-001307-35 ( Registry Identifier: EudraCT )
First Submitted: November 22, 2005
First Posted: November 23, 2005
Results First Submitted: January 8, 2010
Results First Posted: February 26, 2010
Last Update Posted: February 26, 2010
Last Verified: February 2010

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female
Follicle Stimulating Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs